Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
50%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (50.0%)
N/A2 (50.0%)

Trials by Status

recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
completednot_applicable

Simplified Rapid Hydration in Preventing CA-AKI Among Patients With Chronic Kidney Disease

NCT02232997
recruitingphase_3

Pantoprazole in Cisplatin Nephrotoxicity

NCT04217512
completednot_applicable

Bioimpedance Analysis Guided Volume Expansion for the Prevention of Contrast Induced-acute Kidney Injury

NCT02449317
completedphase_3

Prevention of Contrast Renal Injury With Different Hydration Strategies

NCT01218828

Clinical Trials (4)

Showing 4 of 4 trials
NCT02232997Not Applicable

Simplified Rapid Hydration in Preventing CA-AKI Among Patients With Chronic Kidney Disease

Completed
NCT04217512Phase 3

Pantoprazole in Cisplatin Nephrotoxicity

Recruiting
NCT02449317Not Applicable

Bioimpedance Analysis Guided Volume Expansion for the Prevention of Contrast Induced-acute Kidney Injury

Completed
NCT01218828Phase 3

Prevention of Contrast Renal Injury With Different Hydration Strategies

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4